# Pembrolizumab in Early Stage Colon Cancer

> **NCT04231526** · PHASE2 · WITHDRAWN · sponsor: **University of Chicago**

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT04231526
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-20
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** unable to accrue
- **Last updated:** 2024-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04231526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04231526, "Pembrolizumab in Early Stage Colon Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04231526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*